Patents by Inventor Minglin Ma

Minglin Ma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220174962
    Abstract: A composition for detoxifying insect pollinators from one or more organophosphate pesticides, the composition containing microparticles comprising: (i) a phosphotriesterase; (ii) nanoparticles; and (iii) a surface active agent. Also disclosed herein is an aqueous suspension comprising the above-described detoxifying microparticles in an external aqueous medium, which may also contain an insect pollinator attractant. Also described herein is a method for detoxifying insect pollinators of one or more organophosphate pesticides, the method comprising placing the detoxifying aqueous suspension in a location accessible to the insect pollinators to permit the insect pollinators to ingest the detoxifying aqueous suspension, wherein the detoxifying aqueous suspension comprises microparticles, as described above, suspended in an external aqueous medium, typically also including an insect pollinator attractant in the external aqueous medium.
    Type: Application
    Filed: December 7, 2021
    Publication date: June 9, 2022
    Inventors: James Webb, Jing Chen, Minglin Ma
  • Patent number: 11337930
    Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for the encapsulation and transplantation of cells. Also disclosed are high throughput methods for the characterizing the biocompatibility and physiochemical properties of modified alginate polymers.
    Type: Grant
    Filed: October 26, 2020
    Date of Patent: May 24, 2022
    Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Arturo J. Vegas, Minglin Ma, Kaitlin M. Bratlie, Daniel G. Anderson, Robert S. Langer
  • Publication number: 20220118025
    Abstract: The present disclosure is directed to an implantable therapeutic delivery device. This device comprises a hydrogel core; one or more therapeutic agents suspended within the hydrogel core; and an elongated nanofibrous substrate having proximal and distal ends, said nanofiber substrate having an interior nanofiber wall defining an internal space that extends longitudinally between the proximal and distal ends of the substrate, wherein the hydrogel core comprising the one or more therapeutic agents is positioned within the internal space. The disclosure is also directed to methods of delivering a therapeutic agent to a subject in need thereof that involves implanting the device described herein.
    Type: Application
    Filed: October 15, 2021
    Publication date: April 21, 2022
    Inventors: Minglin MA, Xi WANG, James A. FLANDERS
  • Patent number: 11266606
    Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: March 8, 2022
    Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Arturo J. Vegas, Joshua C. Doloff, Omid Veiseh, Minglin Ma, Robert S. Langer, Daniel G. Anderson
  • Publication number: 20220031913
    Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
    Type: Application
    Filed: July 15, 2021
    Publication date: February 3, 2022
    Inventors: Arturo Vegas, Joshua C. Doloff, Omid Veiseh, Minglin Ma, Robert S. Langer, Daniel G. Anderson
  • Publication number: 20210267200
    Abstract: The present application relates to copolymers of N-halamine (HA) and dopamine (DMA) and their method of formation. The HA and DMA are present in the copolymer in a ratio of 0.4:9.6 to 9.6:0.4 (HA: DMA). The copolymers can be used in novel antimicrobial compositions that can be coated, and covalently bonded to surfaces such as metal, plastic, glass, or paint surfaces. The coating provides a rechargeable antimicrobial surface with the treatment of a halogen. The coating thickness and halogen content can be tuned by adjusting the formulation and crosslinking the coating.
    Type: Application
    Filed: June 18, 2019
    Publication date: September 2, 2021
    Inventors: Minglin MA, Randy WOROBO, Mingyu QIAO
  • Patent number: 11090413
    Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: August 17, 2021
    Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE CHILDREN'S MEDICAL CENTER CORPORATON
    Inventors: Arturo Vegas, Joshua C. Doloff, Omid Veiseh, Minglin Ma, Robert S. Langer, Daniel G. Anderson
  • Publication number: 20210186886
    Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for the encapsulation and transplantation of cells. Also disclosed are high throughput methods for the characterizing the biocompatibility and physiochemical properties of modified alginate polymers.
    Type: Application
    Filed: October 26, 2020
    Publication date: June 24, 2021
    Inventors: Arturo J. Vegas, Minglin Ma, Kaitlin M. Bratlie, Daniel G. Anderson, Robert S. Langer
  • Publication number: 20210170072
    Abstract: The present application relates cell replacement devices, comprising a frame cap and a frame base, where the frame cap includes a first connecting member and one or more ports that traverse a thickness of the frame cap. The frame base of the cell replacement device includes one or more walls defining an interior chamber, defining a first opening to the interior chamber on one side of the frame base, and defining a second opening to the interior chamber on another side of the frame base. The first opening of the frame base is configured to receive the frame cap, and the frame base further includes a second connecting member constructed to connect with the first connecting member. The frame base further comprises a mesh disposed adjacent the second opening.
    Type: Application
    Filed: December 7, 2020
    Publication date: June 10, 2021
    Inventors: Duo An, Longhai Wang, Alexander Ernst, James Flanders, Minglin Ma
  • Publication number: 20210069100
    Abstract: Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.
    Type: Application
    Filed: September 17, 2020
    Publication date: March 11, 2021
    Inventors: Minglin Ma, Daniel G. Anderson, Robert S. Langer, Omid Veiseh, Joshua Charles Doloff, Delai Chen, Christian J. Kastrup, Arturo Jose Vegas
  • Patent number: 10898443
    Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: January 26, 2021
    Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Arturo J. Vegas, Joshua C. Doloff, Omid Veiseh, Minglin Ma, Robert S. Langer, Daniel G. Anderson
  • Publication number: 20200390823
    Abstract: The present invention relates to a vascularized therapeutic delivery system. This system includes a preparation of cells encapsulated by a biological support material and a microvascular mesh that at least partially surrounds the biological support material encapsulating the preparation of cells, where the microvascular mesh includes a network of continuous interconnected tubular structures defined by endothelial cells and an extracellular matrix scaffold. Also disclosed are methods for delivering a therapeutic agent to a subject using the vascularized therapeutic delivery system and methods of producing such a vascularized therapeutic delivery system.
    Type: Application
    Filed: February 7, 2019
    Publication date: December 17, 2020
    Inventors: Minglin MA, Wei SONG, Alan CHIU
  • Patent number: 10842753
    Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for the encapsulation and transplantation of cells. Also disclosed are high throughput methods for the characterizing the biocompatibility and physiochemical properties of modified alginate polymers.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: November 24, 2020
    Assignees: Massachusetts Institute of Technology, The Children's Medical Center Corporation
    Inventors: Arturo J. Vegas, Minglin Ma, Kaitlin M. Bratlie, Daniel G. Anderson, Robert S. Langer
  • Patent number: 10835486
    Abstract: Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: November 17, 2020
    Assignees: Massachusetts Institute of Technology, The Children's Medical Center Corporation
    Inventors: Minglin Ma, Daniel G. Anderson, Robert S. Langer, Omid Veiseh, Arturo Jose Vegas, Joshua Charles Doloff, Delai Chen, Christian J. Kastrup
  • Patent number: 10786446
    Abstract: Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: September 29, 2020
    Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Minglin Ma, Daniel G. Anderson, Robert S. Langer, Omid Veiseh, Joshua Charles Doloff, Delai Chen, Christian J. Kastrup, Arturo Jose Vegas
  • Patent number: 10729818
    Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: August 4, 2020
    Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Arturo J. Vegas, Joshua C. Doloff, Omid Veiseh, Minglin Ma, Robert S. Langer, Daniel G. Anderson
  • Patent number: 10709818
    Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: July 14, 2020
    Assignees: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Arturo J. Vegas, Joshua C. Doloff, Omid Veiseh, Minglin Ma, Robert S. Langer, Daniel G. Anderson
  • Publication number: 20200172741
    Abstract: The present application discloses a method of forming a hydrogel-coated substrate, wherein the hydrogel has antifouling and antimicrobial properties. The method comprises applying an aqueous pre-hydrogel solution to a substrate, polymerizing the aqueous pre-hydrogel solution, thereby forming a coated substrate having a conformal hydrogel coating and a non-conformal hydrogel coating, contacting the coated substrate with a swelling agent, and removing the non-conformal hydrogel coating from the coated substrate, thereby leaving the conformal hydrogel coating on the substrate to form the hydrogel-coated substrate. The aqueous pre-hydrogel solution comprises a monomer with antimicrobial activity, a monomer with antifouling activity, and either a polymer, oligomer, or macromer which, when polymerized together, form a hydrogel. Also disclosed is a coated substrate and a hydrogel coating.
    Type: Application
    Filed: November 26, 2019
    Publication date: June 4, 2020
    Inventors: Minglin MA, You YONG, Mingyu QIAO, Qingsheng LIU
  • Publication number: 20200171095
    Abstract: The present invention relates to an implantable therapeutic delivery system, methods of treatment utilizing the implantable therapeutic delivery system, and methods of fabricating the implantable delivery system.
    Type: Application
    Filed: October 29, 2019
    Publication date: June 4, 2020
    Inventors: Minglin MA, James A. FLANDERS, Duo AN
  • Publication number: 20200016085
    Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.
    Type: Application
    Filed: September 26, 2019
    Publication date: January 16, 2020
    Inventors: Arturo J. Vegas, Joshua C. Doloff, Omid Veiseh, Minglin Ma, Robert S. Langer, Daniel G. Anderson